AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Alto dividendo
La empresa es una gran pagadora de dividendos. Su ratio de pago de dividendos más reciente es del 263.76%.
Dividendo estable
La empresa ha pagado dividendos de forma regular durante los últimos 5 años. Su ratio de pago de dividendos más reciente es del 263.76%.
Sobrevalorada
El PE más reciente de la empresa es 115.55, en un rango percentil alto de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 1.36B acciones, lo que supone un aumento del 1.92% con respecto al trimestre anterior.
En posesión de ETHSX
El inversor estrella ETHSX posee 14.48M acciones de este valor.